{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:03:45Z","timestamp":1791623025885,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013430","name":"China Power Investment Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013430","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023542","name":"Centre for Perceptual and Interactive Intelligence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.yrtph.2024.105647","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T01:50:31Z","timestamp":1716256231000},"page":"105647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["New limits proposed for the management of non-mutagenic impurities"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2022-4017","authenticated-orcid":false,"given":"Anja","family":"Slikkerveer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Doehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Claude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0594-8185","authenticated-orcid":false,"given":"Steven","family":"Spanhaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yrtph.2024.105647_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/jfmpc.jfmpc_578_19","article-title":"Trends in FDA drug approvals over last 2 decades: an observational study","volume":"9","author":"Batta","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"10.1016\/j.yrtph.2024.105647_bib2","series-title":"Guideline on the Limits of Genotoxic Impurities","year":"2006"},{"key":"10.1016\/j.yrtph.2024.105647_bib3","series-title":"Reflection Paper on the Qualification of Non-genotoxic Impurities","year":"2018"},{"key":"10.1016\/j.yrtph.2024.105647_bib4","series-title":"Assessment Report. Procedure under Article 5(3) of Regulation EC (No) 726\/2004 Nitrosamine Impurities in Human Medicinal Products","year":"2020"},{"key":"10.1016\/j.yrtph.2024.105647_bib5","article-title":"Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products","volume":"20","year":"2024","journal-title":"EMA\/409815\/2020 Rev"},{"key":"10.1016\/j.yrtph.2024.105647_bib6","series-title":"Guidance for Industry. Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs)","year":"2023"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105647_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0300-483X(00)00228-6","article-title":"The use of Haber's Law in standard setting and risk assessment","volume":"149","author":"Gaylor","year":"2000","journal-title":"Toxicology"},{"key":"10.1016\/j.yrtph.2024.105647_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.105023","article-title":"Calculating qualified non-mutagenic impurity levels: Harmonization of approaches","volume":"126","author":"Graham","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105647_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.yrtph.2016.12.011","article-title":"Management of organic impurities in small molecule medicinal products: deriving safe limits for use in early development","volume":"84","author":"Harvey","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105647_bib10","series-title":"Impurities in New Drug Substances, ICH Q3A(R2)","year":"2006"},{"key":"10.1016\/j.yrtph.2024.105647_bib11","series-title":"Impurities in New Drug Products, ICH Q3B(R2)","year":"2006"},{"key":"10.1016\/j.yrtph.2024.105647_bib12","series-title":"Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, ICH M3(R2)","year":"2009"},{"key":"10.1016\/j.yrtph.2024.105647_bib13","series-title":"Impurities: Guideline for Residual Solvents, ICH Q3C(R8)","year":"2021"},{"key":"10.1016\/j.yrtph.2024.105647_bib14","series-title":"Guideline for Elemental Impurities, ICH Q3D(R2)","year":"2022"},{"key":"10.1016\/j.yrtph.2024.105647_bib15","series-title":"Questions and Answers","article-title":"ICH M7(R2) guideline: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential limit potential carcinogenic risk","year":"2022"},{"issue":"R2","key":"10.1016\/j.yrtph.2024.105647_bib16","article-title":"Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential limit potential carcinogenic risk","volume":"M7","year":"2023","journal-title":"ICH"},{"key":"10.1016\/j.yrtph.2024.105647_bib17","article-title":"Deriving safe limits for process-related organic impurities in medicinal products during clinical development","author":"Kenyon","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105647_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.fct.2003.08.006","article-title":"Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet","volume":"42","author":"Kroes","year":"2004","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105647_bib19","series-title":"Non-mutagenic Impurities \u2013 Recent Industry Experience of Using Dose Durational Limits in Drug Development","author":"Lortie","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105647_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104895","article-title":"Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey","volume":"122","author":"Mitra","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105647_bib21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0278-6915(96)00049-X","article-title":"Correlation of structural class with no-observed-effect levels: a proposal for establishing a threshold of concern","volume":"34","author":"Munro","year":"1996","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105647_bib22","article-title":"Industry approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products","volume":"576","author":"Pokar","year":"2020","journal-title":"Int. J. Pharm. (Amst.)"},{"key":"10.1016\/j.yrtph.2024.105647_bib23","article-title":"Opportunities for use of one species for longer-term toxicology testing during drug development: a cross-industry evaluation","volume":"133","author":"Prior","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105647_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.toxlet.2019.07.019","article-title":"Testing the thresholds of toxicological concern values using a new data base for food-related substances","volume":"314","author":"Reilly","year":"2019","journal-title":"Toxicol. Lett. (Shannon)"},{"key":"10.1016\/j.yrtph.2024.105647_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/acs.oprd.9b00479","article-title":"Control strategy expectations in early clinical phase synthetic oncology programs: two global regulatory case studies","volume":"24","author":"Roberts","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.yrtph.2024.105647_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104524","article-title":"Qualification of impurities based on metabolite data","volume":"110","author":"Weidolf","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024000886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024000886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T12:12:59Z","timestamp":1717243979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":26,"alternative-id":["S0273230024000886"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105647","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New limits proposed for the management of non-mutagenic impurities","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105647"}}